Literature DB >> 26088116

Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System.

Gary Hulse1, Erin Kelty, Sean Hood, Amanda Norman, Maria Rita Basso, Albert Stuart Reece.   

Abstract

This review paper discusses the central role of gamma-aminobutyric acid (GABA) in diverse physiological systems and functions and the therapeutic potential of the benzodiazepine antagonist flumazenil (Ro 15- 1788) for a wide range of disorders of the central nervous system (CNS). Our group and others have studied the potential of flumazenil as a treatment for benzodiazepine dependence. A small but growing body of research has indicated that flumazenil may also have clinical application in CNS disorders such as Parkinson's disease, idiopathic hypersomnia and amyotrophic lateral sclerosis. Despite this body of research the therapeutic potential of flumazenil remains poorly understood and largely unrealized. The purpose of this paper is not to provide an exhaustive review of all possible therapeutic applications for flumazenil but rather to stimulate research interest, and discussion of the exciting therapeutic potential of this drug for a range of chronic debilitating conditions.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26088116     DOI: 10.2174/1381612821666150619092720

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  3 in total

1.  Trigeminal neuropathic pain development and maintenance in rats are suppressed by a positive modulator of α6 GABAA receptors.

Authors:  Dina Vasović; Branka Divović; Marco Treven; Daniel E Knutson; Friederike Steudle; Petra Scholze; Aleksandar Obradović; Jure Fabjan; Božidar Brković; Werner Sieghart; Margot Ernst; James M Cook; Miroslav M Savić
Journal:  Eur J Pain       Date:  2019-02-04       Impact factor: 3.931

2.  Flumazenil for the Treatment of Refractory Hypersomnolence: Clinical Experience with 153 Patients.

Authors:  Lynn Marie Trotti; Prabhjyot Saini; Catherine Koola; Vincent LaBarbera; Donald L Bliwise; David B Rye
Journal:  J Clin Sleep Med       Date:  2016-10-15       Impact factor: 4.062

Review 3.  TGF-β/Smad3 Signalling Modulates GABA Neurotransmission: Implications in Parkinson's Disease.

Authors:  Mª Dolores Muñoz; Nerea de la Fuente; Amelia Sánchez-Capelo
Journal:  Int J Mol Sci       Date:  2020-01-16       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.